TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26746580
Drug: Therapy-as-usual control
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy-as-usual control group (no writing intervention)
Study: 24852722
Drug: BCG vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccination at school age (first dose)
Study: 20609482
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI, escitalopram)
Study: 20609482
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant (TCA, nortriptyline)
Study: 17921366
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (30 g fat/m(2), 35% fat)
Study: 16120118
Drug: Fluconazole capsules
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole capsules (Zolax 50 mg once a day)
Study: 16120118
Drug: Hexetidine mouthrinses
Normalized name: Hexetidine
DrugBank: Hexetidine (DB08958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexetidine mouthrinses (Heksoral 0.1%, twice daily)
Study: 16120118
Drug: Fluconazole capsules
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole capsules and hexetidine mouthrinses for 14 days
Study: 11934186
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment (debridement and short-term usage of antimicrobial agents)
Study: 8695556
Drug: Peribulbar injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injections of 5 ml of anaesthetic (study group 1)
Study: 8695556
Drug: Peribulbar injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injections of local anaesthetic (study group 2)
Study: 28467859
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg)
Study: 31145202
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) alone (0.625 mg/d)
Study: 31145202
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + medroxyprogesterone acetate (MPA) (0.625 mg of CEE + 2.5 mg of MPA)
Study: 20642246
Drug: Oxycodone HCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone HCI IR 10 or 15 mg
Study: 17643772
Drug: 3 intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intradermal doses of 0.1 mL PCECV (Rabipur)
Study: 17643772
Drug: 2 simulated
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 simulated post‐exposure booster doses 1 year after primary vaccination
Study: 16224180
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with biweekly administration of 1,000 mg/m² gemcitabine
Study: 2643772
Drug: High-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subcutaneous heparin (12,500 units every 12 hours)
Study: 2643772
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous heparin (5000 units every 12 hours)
Study: 2643772
Drug: High-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subcutaneous heparin
Study: 1104060
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous heparin
Study: 7409300
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg o.d.)
Study: 7409300
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg t.i.d.)
Study: 29962180
Drug: Rosuvastatin in
Normalized name: Product containing rosuvastatin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin in combination with nimodipine
Study: 29687966
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation plus laser therapy and exercise (SM-LT-CE)
Study: 29687966
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy and exercise (LT-CE)
Study: 22824834
Drug: 12 mcg/h
Normalized name: fentanyl 12 MCG/HR 3 Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mcg/h fentanyl patch
Study: 22824834
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control patch
Study: 17517060
Drug: Methodological and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methodological and statistical features of RCTs in implant therapy
Study: 28117496
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel
Study: 10527977
Drug: Norplant implants
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norplant implants (NOR)
Study: 7588177
Drug: Antidepressants (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (full dosage)
Study: 7588177
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term antidepressants (in bipolar disorders)
Study: 7588177
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term antidepressants (in dysthymias and personality disorders)
Study: 7588177
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term antidepressant treatment
Study: 2012292
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia with higher infusion rate
Study: 2012292
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia with lower infusion rate
Study: 7044724
Drug: Oral preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral preoperative antibiotics and systemic peroperative antibiotics
Study: 7044724
Drug: Oral preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral preoperative antibiotics
Study: 7044724
Drug: Systemic peroperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic peroperative antibiotics
Study: 29961920
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human EPO (rhEPO) administered acutely to healthy humans.
Study: 29961920
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human EPO (rhEPO) administered acutely to mice.
Study: 29961920
Drug: Acute injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute injections of recombinant FGF23.
Study: 23299013
Drug: Quadrivalent HPV-6/11/16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV-6/11/16/18 vaccine
Study: 22209292
Drug: Monovalent HPV-16
Normalized name: HPV 16 E7/HSP65 vaccine
DrugBank: Verpasep caltespen (DB04959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent HPV-16 vaccine
Study: 17201904
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patches with behavioural support
Study: 17201904
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patches with behavioural support
Study: 10612536
Drug: Cytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine treatment (placebo-controlled)
Study: 30398862
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro assessment of melanin binding properties of small molecules
Study: 27317305
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of peramivir 150 mg
Study: 27317305
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of peramivir 300 mg
Study: 27317305
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of peramivir 600 mg
Study: 27317305
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of peramivir 600 mg
Study: 20384415
Drug: Sequential name‐face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential name‐face matching task with famous faces
Study: 20384415
Drug: Sequential name‐face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential name‐face matching task with nonfamous faces
Study: 20384415
Drug: Sequential face-name
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential face-name matching task with names
Study: 12005458
Drug: Late enteral
Normalized name: Soy protein isolate enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late enteral feeding (started on day 5, with 20% of estimated daily requirements during the first 4 days)
Study: 10424513
Drug: IV levofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV levofloxacin, 500 mg qd for 7 days
Study: 10424513
Drug: IV alatrofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV alatrofloxacin, 200 mg qd for 7 days
Study: 2207399
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg/kg over three days
Study: 2207399
Drug: Pyrimethamine 75
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine 75 mg and sulfadoxine 1500 mg as a single dose
Study: 2207399
Drug: Chlorproguanil 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil 1.2 mg/kg and dapsone 2.4 mg/kg as a single dose
Study: 30633917
Drug: Regular vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular vaginal assessments (4-hourly prior to each oral misoprostol dose)
Study: 23504383
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg every other week for 24 weeks
Study: 19546510
Drug: Excimer laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer laser treatment
Study: 15247354
Drug: Doxorubicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin alone (30 mg/m² every three weeks for 10 doses)
Study: 15247354
Drug: Dexrazoxane (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexrazoxane (300 mg/m²) followed by doxorubicin
Study: 11770708
Drug: Low-dose pravastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pravastatin (5 mg/day)
Study: 11770708
Drug: Standard-dose pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose pravastatin (10-20 mg/day)
Study: 11830951
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy applied during and following third molar removal
Study: 11830951
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active additional laser treatment (placebo)
Study: 23886027
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 1200 mg/day + risperidone
Study: 16800986
Drug: Kanlijian (KLJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanlijian (KLJ) combined with conventional therapy
Study: 31928920
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) granules based on syndrome differentiation (Bao‐fei Hua‐xian granule, Jin‐shui Huan‐xian granule, Yang‐qing Kang‐xian granule)
Study: 29051138
Drug: Physiotherapist-guided Ambulant
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist-guided Ambulant Activity Feedback (AAF) therapy (n=62)
Study: 29051138
Drug: Psychologist-guided Web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychologist-guided Web-based mindfulness-based cognitive therapy (eMBCT; n=55)
Study: 22728693
Drug: Single MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single MRI slice 5-10 cm above L(4)-L(5)
Study: 22728693
Drug: Single MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single MRI slice L(4)-L(5)
Study: 17561998
Drug: Vehicle instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle instillation (100 ml of 10% ethanol in saline)
Study: 17561998
Drug: RTX instillation
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX instillation (100 ml of 50 nM RTX in 10% ethanol in saline)
Study: 15447895
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) supplementation (3.0 g/d; 50:50 blend of cis-9,trans-11 CLA and trans-10,cis-12 CLA)
Study: 9742535
Drug: Penile block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile block plus diclofenac suppository (Group 2)
Study: 9742535
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository alone (Group 3)
Study: 1089363
Drug: L-tryptophan alone
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan alone
Study: 1089363
Drug: L-tryptophan combined
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan combined with L-dopa
Study: 1089363
Drug: L-dopa combined
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa combined with L-tryptophan
Study: 28488449
Drug: Individualized medication
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized medication training (20 min)
Study: 28488449
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without training
Study: 19692788
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality therapy (30 mins per session, in addition to conventional therapy)
Study: 19692788
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (40 mins a day, 4 days a week for 4 weeks)
Study: 15015820
Drug: Euphyllin Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin Retard 350 mg under fasting condition
Study: 15015820
Drug: Euphyllin Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin Retard 350 mg with breakfast
Study: 11168211
Drug: Astra-Tech (A)
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astra-Tech (A) system - self-tapping TiO2-blasted screw-shaped implants made of commercially pure titanium
Study: 11168211
Drug: Brånemark (B)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark (B) system - self-tapping Mark II implants with machined surface irregularities
Study: 7069070
Drug: Oral breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral breathing
Study: 9504133
Drug: Oral breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral breathing at 60 W
Study: 8439713
Drug: Xylocaine/proliferant injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine/proliferant injections
Study: 8439713
Drug: Xylocaine/saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine/saline solution injections
Study: 19846796
Drug: Closed-loop intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop intraperitoneal insulin infusion
Study: 29804377
Drug: ETV monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV monotherapy
Study: 20305865
Drug: Systemic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic metronidazole plus amoxicillin (AP+AB)
Study: 20305865
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing with placebo tablets (CP)
Study: 18534556
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 1 g twice daily adjunctive to usual medication
Study: 12074271
Drug: Aprindine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprindine (40 mg/day)
Study: 8125424
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg/day)
Study: 29525822
Drug: Ticagrelor (180-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180-mg loading dose, 90 mg twice daily thereafter)
Study: 30898608
Drug: Clopidogrel (300-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300- to 600-mg loading dose, 75 mg daily thereafter)
Study: 21613575
Drug: Quercetin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (2,000 mg/day)
Study: 9420539
Drug: Wax-carbon-laser treatment
Normalized name: Candelilla Wax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax-carbon-laser treatment
Study: 9420539
Drug: Wax-laser treatment
Normalized name: Candelilla Wax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax-laser treatment
Study: 30144985
Drug: Placebo (mock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mock laser therapy)
Study: 12795770
Drug: Alefacept 15
Normalized name: alefacept 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 15 mg IM
Study: 12795770
Drug: Alefacept 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 10 mg IM
Study: 1871078
Drug: Nurse-assisted combination
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-assisted combination intervention
Study: 6137857
Drug: Zopiclone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 10 mg
Study: 30957654
Drug: Labeling condition
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeling condition (e.g., 'sex offenders', 'murderers')
Study: 30957654
Drug: Neutral condition
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral condition (e.g., 'people who have committed crimes of a sexual nature')
Study: 30452511
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene gel, 0.1%, applied once every night for 3 months.
Study: 30452511
Drug: Microneedling therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling therapy with a dermaroller (1.5 mm needle length) for a total of 4 sessions over 3 months.
Study: 24848975
Drug: PRGF (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRGF (one dose)
Study: 24848975
Drug: PRGF (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRGF (two doses)
Study: 24848975
Drug: PRGF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRGF plus HA (two doses)
Study: 21734512
Drug: 20-hour manualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-hour manualized group cognitive behavior therapy program
Study: 19521894
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid 16.7 mg
Study: 19521894
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid up to 50.1 mg
Study: 19521894
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (all doses)
Study: 9150621
Drug: BMS 180048
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS 180048 150 mg
Study: 9150621
Drug: BMS 180048
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS 180048 200 mg
Study: 8122735
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia and postoperative intravenous morphine infusion (GA)
Study: 2442559
Drug: lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 5 mg/day
Study: 2442559
Drug: captopril 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 37.5 mg/day
Study: 29410934
Drug: Flexible-dose lurasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible-dose lurasidone (40 to 160mg/d)
Study: 29410934
Drug: Flexible-dose quetiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible-dose quetiapine XR (200 to 800mg/d)
Study: 21346065
Drug: Hesperidin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hesperidin (500 mg once daily for 3 weeks)
Study: 18564150
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 or 100 mg, as needed)